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Objective: This article aims to investigate the expression of vacuolar-H + −ATPase (V-ATPase) in non-small cell lung
cancer (NSCLC) and its variations with pathological type and grade. Furthermore, to evaluate the chemotherapy
drug sensitivity of different cancer tissues as well as its correlation with V-ATPase expression in NSCLC.
Methods: V-ATPase expression was examined in 92 NSCLC tissue samples using the immunohistochemical Envision
method and immunofluorescence assay. The location of V-ATPase expression was observed by confocal laser
scanning microscopy and the difference of its expression rate was evaluated. The sensitivity of cancer tissues to
chemotherapy drug was examined using MTT assay and its correlation with the V-ATPase expression was tested in
NSCLC by Spearman rank correlation analysis.
Results: V-ATPase expression was mainly localized in the cell membrane and cytoplasm. The expression rate of
V-ATPase was 71.43% in squamous cell lung cancer, significantly lower than that of the lung adenocarcinoma (83.72%,
P = 0.000). In different pathological grades of squamous cell lung cancer, the expression rate of V-ATPase was 58.33% in
grade II, significantly lower than that of the grade III (84.00%, P = 0.014). The expression rate of V-ATPase in grade II lung
adenocarcinoma was 76.67%, significantly lower than that of the grade ΙΙΙ adenocarcinoma (100.0%, P = 0.012).
Correlation analysis showed that the sensitivity of NSCLC tissues to cyclophosphamide, gemcitabine, doxorubicin,
paclitaxel and cisplatin was significantly correlated with the V-ATPase expression rate (P < 0.05).
Conclusions: V-ATPase was overexpressed in NSCLC. The expression of V-ATPase was related to the pathological type
and grade of cancer and was likely associated with chemotherapy drug resistance in NSCLC.
Virtual slides: The virtual slide(s) for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/vs/
7515811511020000
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The morbidity and mortality of lung cancer have in-
creased over the years. Lung cancer has become the
leading malignancy in patients, causing great threats to
human health. At present, lung cancer is commonly
treated with multidisciplinary treatment strategies, of
which chemotherapy is the primary approach. However,* Correspondence: zzpchest@126.com; lxfchest@126.com
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reproduction in any medium, provided the orchemotherapy drug resistance is an important cause of
treatment failure in lung cancer [1-3]. Researchers
showed that an acidic microenvironment can signifi-
cantly affect the malignant behaviors of cancer cells re-
lated to invasion, metastasis and drug resistance [4,5].
The drug resistance of cancer cells is likely to be related
to the changes in pH gradient between the extracellular
environment and the cytoplasm. Vacuolar-H + −ATPase
(V-ATPase) plays a major role in the regulation of cellu-
lar pH conditions [6,7].
Previous studies focused on V-ATPase were mainly
conducted on cancer metastasis and invasion aspectsThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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correlation between V-ATPase expression and drug re-
sistance in tumor cells. In this study, we examined the
expression of V-ATPase in different pathological types of
non-small cell lung cancer (NSCLC) by immunohisto-
chemical and immunofluorescence assays, followed by
the evaluation of the drug resistance in NSCLC tissues.
The results were used to explore the correlation between
V-ATPase expression and chemotherapy drug resistance
in NSCLC. This work presents the first evidence of high
V-ATPase expression in NSCLC. The expression of
V-ATPase was shown to be related to the pathological
type and grade of the cancer and might be associated
with the chemotherapy drug resistance in NSCLC.
Materials and methods
During May 2011 to April 2012, clinical specimens were
collected from 92 patients of primary NSCLC who
underwent thoracic surgery in Tangdu Hospital, Fourth
Military Medical University. The patients included 66
males and 26 female with an average age of 63.2 ± 13.1.
All patients were classified according to the lung cancer
classification and the evaluation criteria were jointly an-
nounced by the International Society for the Study of
Lung Cancer, the American Thoracic Society and the
European Respiratory Society. The experiments were
conducted with NSCLC specimens of two histological
types of lung cancer including squamous cell lung can-
cer and adenocarcinoma (Table 1).
All the 45 smoking patients were male and pack-years
of them were fifteen in average. There were 12 female
patients suffered passive smoking. 23 female patients
had the history of exposure to cooking fume and one to
asbestos. 22 people have exposure history of diesel ex-
clusion, which were include 17 male patients and 5 fe-








TNM stages, n (%)
II 54(58.70)
III 38(41.30)
Cell types, n (%)
Squamous cell lung cancer 49(71.42)
Lung adenocarcinoma 43(83.72)Immediately after the clinical specimens were col-
lected in the surgery, 1.5–2.0 cm3 specimens were cut
and placed in sterile tubes pre-filled with sterile RPMI
1640 culture medium. Part of the fresh cancer tissue was
used for testing the susceptibility to chemotherapy
drugs. The specimens were fixed with 10% formalin and
were embedded in paraffin after routine dehydration and
transparency. Histopathological typing and grading were
performed by the Department of Pathology and clinical
typing after the surgery. All patients agreed to sign writ-
ten informed consents. The study was approved by the
Ethics Committee of the hospital.
Reagents
The V-ATPase protein antibody (commercialized mouse
anti-human, Molecular Probes) was purchased from
Jingmei (Shenzhen, China). An Envision™ kit for immu-
nohistochemical analysis (Dako) and the secondary anti-
body for immunofluorescence assay were purchased
from Santa Crus Biotechnoloty (Shanghai, China).
Chemotherapy drugs including: cyclophosphamide,
gemcitabine, doxorubicin, paclitaxel and cisplatin were
purchased from Jiangsu Ruiheng Co., Ltd (Lianyungang,
China), Lilly France (Fegersheim, France), Zhejiang Hisun
Pharmaceutical Corporation (Zhejiang, China), Bristol-
Myers Squibb Co. (Tokyo, Japan) and Shandong Qilu
Pharmaceutical Co., Ltd (Jinan, China), respectively. The
RPMI1640 media was purchased from Gibco Co (CA,
USA). Fetal bovine serum was purchased from Zhejiang
Tianhang Biological Technology Co., Ltd (Hangzhou,
China). Trypsin was purchased from Hyclone Co. (Logan,
UT, USA.). The MTT and DMSO were purchased from
Sigma-Aldrich (St. Louis, MO, USA).
Cell suspension preparation and drug sensitivity test
Fresh cancer tissue was repeatedly washed with saline
solution containing penicillin-streptomycin. After the fat
and necrotic tissues were removed, the cell suspension
was prepared with the cancer tissue and was filtered
through a 200-mesh sieve of steel-net. The cell density
in the suspension was adjusted to 5 × 105 to 107/ml with
the 1640 complete culture medium and the cells were
counted by trypan blue staining. The diluted cell suspen-
sion was inoculated to 96-well culture plates (190 μl/
well) in four groups including: blank, control and experi-
mental groups of high- and low-level drug groups (four
wells per group). The inoculated plates were incubated
at 37°C in a 5%-CO2 incubator for 24 h. In the next step,
10-μl aliquots of the abovementioned chemotherapy
drugs were added to the high-level drug group with final
concentrations adjusted to the human plasma concentra-
tion (12, 2, 0.4, 0.5 and 1 mg/ml, respectively). The
drugs used in the low-level drug group were correspond-
ingly diluted four times.
Figure 1 Expression of V-ATPase in NSCLC. (A): squamous cell lung cancer; (B): lung adenocarcinoma; (A,B): positive staining of V-ATPase in
the plasma membrane and cytoplasm; (C): blank (EnVision; 400×).
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After 48-h incubation, 20 μl of MTT reagent (5 mg/ml)
was added to each well. The plates were incubated for
4 h. The culture supernatant was removed and 150 μl of
DMSO was added to each well. The plates were oscil-
lated for 5 min to dissolve MTT formazan crystals. The
absorbance of each well was determined at 570 nm using
a microplate reader.Calculation of the drug sensitivity
Calculation of drug inhibition rate (IR)
The drug inhibition and cell survival rates were calcu-
lated based on the following formula:
Drug inhibition rate (%) = (Optical density of control
group-optical density of drug
group)/(optical density of
control group-optical dens-
ity of blank group) × 100%
Cell survival rate = Drug group/Control groupCriteria for chemotherapy drug sensitivity
The criteria for chemotherapy drug sensitivity as follow-
ings: the IR of less than 30% was considered as drug
resistance; 30–50% as low sensitivity; higher than 50%
as medium sensitivity and higher than 70% as high
sensitivity.Figure 2 Location of V-ATPase in NSCLC. (A): squamous cell lung cance
the plasma membrane and cytoplasm (1000×).Immunohistochemical assay of V-ATPase protein
The specimens were prepared as 5-μm serially sectioned
slides and were used for HE and immunohistochemical
staining. The immunohistochemical staining included
two steps (Envision™). First, the slices were dewaxed to
water, digested with urea and blocked with 3% hydrogen
peroxide. After the microwave repair with a citric acid
buffer, the slides were cooled, blocked with 10% goat
serum and incubated with the primary antibody at 4°C
overnight. Second, the slides were taken from the re-
frigerator and were recovered to 37°C. The anti-rabbit
secondary antibody (EnVision) was added for reaction at
37°C temperature. The slides were washed with phos-
phate buffer saline (PBS) between each intermediate step.
After the diaminobenzidine staining, the slides were exam-
ined by microscopy. The staining was terminated and the
slides were slightly stained with hematoxylin. After dehy-
dration and transparency treatments, the slides were ex-
amined by light microscopy. The control group was
prepared with positive, negative and blank controls.Immunofluorescence assay of V-ATPase protein
The specimens were incubated with the primary anti-
body following the same procedure as described above.
The slides were recovered to 37°C on the following day
and TRITC-labeled red fluorescent anti-mouse antibody
was added. The slides were incubated at 37°C for
40 min, washed with PBS, mounted with glycerin, exam-
ined by laser confocal microscopy and photographed.r; (B) and (C): lung adenocarcinoma; positive staining of V-ATPase in
Table 2 Expression of V-ATPase in different differentiations of NSCLC
Typing n Pathological
grading




Squamous cell lung cancer 49 II 10 14 0 58.33 U = 195.0 U = 593.5
III 4 17 4 84 p = 0.014
Lung adenocarcinoma 43 II 7 11 12 76.67 U = 101.0 p = 0.000
III 0 2 11 100 p = 0.000
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The V-ATPase protein expression was mainly localized
in the cytoplasm and nuclear membrane. According to
the semi-quantitative integration method, five random
fields of view were observed for each specimen at high
magnification (×400). The results were scored based on
the following criteria: First, positive cells (≤5%: 0; 6–
25%: 1; 26–50%: 2; 51–75%: 3 and >75%: 4). Second,
positive intensity (yellow: 1; brown: 2 and tan: 3). Third,
cell positive rate integrally multiplied by the staining inten-
sity: [(0: negative (−), 1–4: weakly positive (+); 5–8: moder-
ately positive (++) and 9–12: strongly positive (+++)] [11].
Statistical methods
Statistical analysis was performed with SPSS software.
Data comparison among squamous cell carcinoma and
adenocarcinoma, pathological grades of squamous cell
carcinoma, and pathological grades of adenocarcinoma
were done using the Mann–Whitney U rank sum test.
The correlation between the drug sensitivity of cancer
tissues and the expression of V-ATPase was analyzed by
Spearman rank correlation analysis. The rank correlation
coefficients were expressed as rs (P < 0.05, rs < −0.3 was
considered as negatively correlated).
Results
Immunohistochemistry and immunofluorescence data
The results of the immunohistochemical assay showed
that the V-ATPase expression was mainly localized in
the cell membrane and cytoplasm (Figure 1), whereas
the immunofluorescence staining was mainly localized
in the cell membrane (Figure 2). The total expression
rate of V-ATPase in squamous cell lung cancer was
71.43% (Table 2), significantly lower than that of the lung
adenocarcinoma (83.72%, P = 0.000). Among differentTable 3 The correlation of V-ATPase expression with drug sen
V-ATPase Cyclophosphamide Gemcitabine Doxorub
R LS MS HS p value R LS MS HS p value R LS
_ 0 12 6 3 χ2 =
53.3
0 4 11 6 χ2 =
48.13
0 3
+ 14 26 4 0 p =
0.000
6 12 24 2 p =
0.000
16 10
++ 24 3 0 0 rs =
−0.697
14 13 0 0 rs =
−0.654
15 11pathological grades of squamous cell lung cancer, the ex-
pression rate of V-ATPase was 58.33% in grade II, signifi-
cantly lower than that of the grade III (84.00%, 0.014). As
for the adenocarcinoma, the expression rate of V-ATPase
was 76.7% in grade II adenocarcinoma (Table 2), signifi-
cantly lower than that of the grade III adenocarcinoma
(100.0%, P = 0.012).
Correlation between cancer tissue chemotherapy drug
sensitivity and associated V-ATPase expression
The sensitivity of the lung cancer tissues to cyclophos-
phamide, gemcitabine, doxorubicin, paclitaxel, and cis-
platin and the expression of V-ATPase in NSCLC tissues
had a P value of less than 0.05. The corresponding correl-
ation coefficients (rs) were -0.697, -0.654, -0.598, -0.216
and -0.604, respectively (Table 3). Similarly, the P-values
of the correlation test was less than 0.05 (Table 4) for
cyclophosphamide, gemcitabine, doxorubicin, paclitaxel,
and cisplatin in squamous cell lung cancer (rs = -0.584,
-0.512, -0.544, -0.269 and −0.306, respectively). Further-
more, the P-values of the correlation test was less than
0.05 (Table 5) for cyclophosphamide, gemcitabine, doxo-
rubicin and cisplatin (rs = -0.742, -0.607, -0.63, -0.349
and −0.707).
Discussion
Although antineoplastic agents have an important role
in the treatment of NSCLC, their treatment efficiency is
commonly low due to the tumor cell resistance. The
membrane transport proteins play a key role in drug me-
tabolism. In particular, the drug efflux process mediated
by ATP-binding cassette (ABC) transporter plays a
major role in the chemotherapy drug resistance in can-
cer cells [7]. A large body of work has been conducted
on the drug resistance-related Multi-drug resistance 1sitivity in NSCLC
icin Paclitaxel Cisplatin
MS HS p value R LS MS HS p value R LS MS HS p value
6 12 χ2 =
41.09
1 0 2 18 χ2 =
22.35
2 2 8 9 χ2 =
46.9
12 6 p =
0.000
1 1 10 32 p =
0.001
6 13 17 8 p =
0.000
1 0 rs =
−0.598
6 3 7 11 rs =
−0.216
21 4 1 1 rs =
−0.604
Table 4 The correlation of V-ATPase expression with drug sensitivity (resistance) in squamous cell lung cancer
V-ATPase Cyclophosphamide Gemcitabine Doxorubicin Paclitaxel Cisplatin
R LS MS HS p value R LS MS HS p value R LS MS HS p value R LS MS HS p value R LS MS HS p value
_ 0 3 2 2 χ2
=30.12
0 2 3 2 χ2 =
24.143
0 2 0 5 χ2 =
34.11
0 0 0 0 χ2 =
10.03
0 0 2 5 χ2 =
32.88
+ 4 7 2 0 p = 0.00 3 6 4 0 p =
0.000
0 4 5 1 p =
0.000
0 1 5 7 p =
0.124
3 3 6 1 p =
0.000
++ 20 3 0 0 rs =
−0.742
12 11 0 0 rs =
−0.607
0 9 1 0 rs =
−0.630
4 3 5 11 rs =
−0.349
17 4 1 1 rs =
−0.707
R: Resistance; LS: Low sensitivity; MS: Moderate sensitivity; HS: High sensitivity.
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and ATP-binding cassette transporter 2 (ABCG 2),
which function through different mechanisms [12-16].
Molecular mechanisms of tumor cell resistance were
another hot point. It was found that molecular patho-
logical pathways of lung cancer were related with poten-
tial drug influence also. Structural of EGFR changes
leading to the activating properties. Insertions in exon
19 are likely to respond to TKI therapy [17]. Lung
adenocarcinoma with predominant SMPC (stromal inva-
sive micropapillary component) may be associated with
a poor prognosis and have different phenotypic and
genotypic characteristics [18].
ATPase ion pump is an ATP-dependent active trans-
port carrier, which transports Na+, K+, H+, Ca2+ and Cu2+
out of the cells and organelles. V-ATPase is a macromol-
ecular complex enzyme of ATPase and is expressed on the
vacuolar membrane of cytoplasm (microsome), as well as
the cell membrane. V-ATPase produces or maintains the
transmembrane electrochemical ionic gradient that is re-
lated to the accumulation, intracellular distribution and
sensitivity of the anticancer drugs [19]. The over-
expression of V-ATPase in tumor cells is of great signifi-
cance to the maintenance of cytoplasmic alkaline
environment, promotion of tumor cell growth, improve-
ment of the extracellular acid environment, promotion of
cell invasion and metastasis [8,20]. Furthermore, it induces
the invasive phenotype in the tumor cells [21,22]. The
transport capacity of ABCG2 for methotrexate, folic acid,
mitoxantrone and topotecan can be enhanced under low
pH conditions in tumor cell lines, such that at pH 5.5, the
transport capacity of ABCG2 for drugs is five times higherTable 5 The correlation of V-ATPase expression with drug sen
V-ATPase Cyclophosphamide Gemcitabine Doxorub
R LS MS HS p value R LS MS HS p value R LS
_ 0 9 4 1 χ2 =
20.68
0 2 8 4 χ2 =
21.45
0 1
+ 10 19 2 0 p =
0.002
3 6 20 2 p =
0.002
13 6
++ 4 0 0 0 rs =
−0.584
2 2 0 0 rs =
−0.512
2 2
R: Resistance; LS: Low sensitivity; MS: Moderate sensitivity; HS: High sensitivity.than that of the normal conditions [23,24]. The drug re-
sistance could be possibly related to the changes in the pH
gradient between the extracellular environment and the
cytoplasm. It is believed that V-ATPase plays a major role
in the regulation of intracellular pH value [25-27]. Avail-
able data on V-ATPase have mainly been reported based
on the plant studies [28,29] with the exception of a few re-
ports on liver, breast, pancreatic, esophageal, gastric car-
cinomas as well as melanoma cells [8-11]. However, no
reports are available on the correlation between the
V-ATPase expression in NSCLC and the drug resist-
ance in the relevant cancer tissues.
In this study, the results of the immunohistochemical
and immunofluorescence assays showed that V-ATPase
was overexpressed in NSCLC, while its expression rate
was significantly lower in the adjacent normal tissue
(data not shown). In terms of different histological types
of NSCLC, the V-ATPase expression rate was 71.43%
and 83.72% in squamous cell lung cancer and lung
adenocarcinoma. The Mann–Whitney rank sum test
indicated that there were significant differences in the
V-ATPase expression rate between the two cancer tissues
(P < 0.001). The rank sum test among different grades of
squamous cell lung cancer and different differentiation de-
grees of adenocarcinoma further showed significant differ-
ences (P = 0.014 and 0.012, respectively). These results
suggested that was overexpressed in NSCLC. Further-
more, it was demonstrated that the V-ATPase expression
rate of lung adenocarcinoma was higher than that of the
squamous cell lung cancer and higher in grade ΙΙΙ adeno-
carcinoma than that of the well-differentiated adenocar-
cinoma. In clinical practice, it is commonly found thatsitivity (resistance) in lung adenocarcinoma
icin Paclitaxel Cisplatin
MS HS p value R LS MS HS p value R LS MS HS p value
6 7 χ2 =
17.47
1 0 2 11 χ2 =
15.12
2 2 6 4 χ2 =
21.04
7 5 p =
0.008
1 0 5 25 p =
0.004
5 10 11 7 p =
0.002
0 0 rs =
−0.544
2 0 2 0 rs =
−0.269
4 0 0 0 rs =
−0.306
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drugs than squamous cell lung cancer, and that the resist-
ance level is often related to the degree of malignancy. To-
gether these findings indicated that the V-ATPase
expression could be potentially related to the drug resist-
ance in NSCLC.
In order to further examine the relationship between
the V-ATPase expression and the drug resistance in
NSCLC, we carried out the cancer tissue drug sensitivity
test. Spearman rank correlation analysis was performed
for the results of the drug sensitivity test of cyclophospha-
mide, gemcitabine, doxorubicin, paclitaxel and cisplatin in
NSCLC tissues and for the V-ATPase expression in the
corresponding tissues. All the obtained P-values were less
than 0.05 and all the coefficients of rank correlation were
less than −0.30. The correlation was found to be higher in
lung adenocarcinoma as compared to that of the squa-
mous cell lung cancer. However, this correlation was not
significant for paclitaxel when tested separately in squa-
mous cell lung cancer and lung adenocarcinoma. Overall,
there was a negative correlation between the V-ATPase
expression and drug sensitivity in the NSCLC tissues.
Therefore, the V-ATPase expression had a strong positive
correlation with the drug resistance in the NSCLC tissues.
This finding suggested that the V-ATPase expression
could be related to the drug resistance in the NSCLC tis-
sues. The V-ATPase expression rate had a stronger correl-
ation with the drug resistance in the lung adenocarcinoma
tissue as compared to that of the squamous cell lung can-
cer tissue.
Although this study did not prove that the expression
of V-ATPase was directly linked to the drug resistance
of cancer tissues, other experiments have already shown
that the activity of V-ATPase was increased in
multidrug-resistant cell lines. Its subunit genes were
upregulated under the action of antineoplastic agents
[30,31]. Therefore, we speculated that V-ATPase was re-
lated to the drug resistance in tumor tissues. However,
further experiments are needed to unravel the exact
mechanism.
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